



Company presentation  
*March 2022*

# FORWARD LOOKING STATEMENT

---

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on the company's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the company could differ materially from those described in or implied by the statements in this presentation.

This presentation contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information about our current expectations for future events, including potential results of operations, the timing of clinical trials, the timing of regulatory filings and approvals, the timing and outcomes of regulatory or intellectual property decisions, demand for our products in development and the clinical benefits, safety profile and commercial potential and potential pricing of any product candidates. These forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, including those associated with COVID-19 pandemic, and other factors that could cause our actual results, performance or achievements to be materially different than any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our management's beliefs and assumptions only as of the date of this presentation. You should read our most recent filings with the Securities and Exchange Commission including our Transition Report on Form 10-K and our Quarterly Reports on Form 10-Q, including the Risk Factors set forth therein and the exhibits thereto, and our subsequent filings with the Securities and Exchange Commission, completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

# Global Leader in the development of cannabinoid-based antitumor medicine

---

## Development pipeline:

2 Colorectal Cancer Drug Candidates

---

3 Additional Cancers Drug Candidates

---

2 Neuropsychiatric Drug Candidates (early discovery stage)



# CORPORATE STRATEGY

## Drug Discovery Platform:

### Drug Discovery

Conduct all screening and pre-clinical research at in-house state of the art laboratory facilities

### Intellectual Property

Expand and protect the technology, inventions, and trade secrets that are critical for business development



**Drug Candidates**

### AI Based Bioinformatics

Leverage proprietary bioinformatics platform to develop novel cannabinoid formulations & research programs

### Regulatory Affairs

FDA targeted Regulatory Affairs strategy & clinical development programs

# THE CANNABICS APPROACH

---


Cannabics's revolutionary lab uses a bioinformatics platform for rapid evaluation of the therapeutic effects of thousands of cannabinoid compounds against a growing library of cancer cell lines and biopsies. Features of the platform include:



High-throughput and high-content screening



Fully integrated research and development



Custom matrix of cancer cell lines and cannabinoid compounds



In-vivo studies & experiments




Database of biological response data



Regulatory Affairs expertise

# DRUG DISCOVERY



# IP

---

## Patent portfolio consisting of 5 patent families:

4 Granted patents

18 Pending applications

- Methods
- Systems
- Compositions

- 
- Drug Discovery
  - Personalized medicine
  - Precancerous tumors
  - Antitumor



# DRUG CANDIDATES

---

## Development Pipeline:

### Colorectal Cancer:


- Colorectal Cancer
- Precancerous Polyps

### Additional Cancers:

- Melanoma
- Breast Cancer
- Prostate Cancer

### Neuropsychiatry:

- NP-01 (Early discovery stage)
- NP-02 (Early discovery stage)



# MARKET: \$76.1B

---

## (2019 ESTIMATES)

### Colorectal Cancer:

○ Colorectal Cancer	<b>\$18B</b>
○ Precancerous Polyps	<b>\$15B</b>

---

### Additional Cancers:

○ Melanoma	<b>\$6B</b>
○ Breast Cancer	<b>\$22B</b>
○ Prostate Cancer	<b>\$7.5B</b>

---

### Neuropsychiatry:

○ NP-01 (Early discovery stage)	<b>\$6.6B</b>
○ NP-02 (Early discovery stage)	<b>\$1B</b>

---



# REGULATORY PATHWAY

Product/clinical path	Discovery	Preclinical		Clinical		
		In-vitro	In-vivo	Phase I	Phase II (a)	Comments
<b>Colorectal Cancer</b>						
Cannabics® RCC-33 Colorectal Cancer	Completed		Completed	Upcoming	2023-2025	Launch Phase I/II (a) by Q3 of 2023
Cannabics® PLP-33 Pre-cancerous Polyps	Completed		Upcoming	Upcoming	2022-2024	Complete Phase I by end of 2024
<b>Additional Cancers</b>						
Cannabics® MLN-33 Melanoma	Completed		Upcoming	Upcoming	2022-2023	Complete Pre-IND by end of 2023
Cannabics® BRST-33 Breast Cancer	Completed		Upcoming	Upcoming	2022-2023	Complete Pre-IND by end of 2023
Cannabics® PRST-33 Prostate Cancer	Completed		Upcoming	Upcoming	2022-2023	Complete Pre-IND by end of 2023
<b>Neuropsychiatry</b>						
NP-01	Upcoming	[N/A]				Preclinical strategy TBD
NP-02	Upcoming	[N/A]				Preclinical strategy TBD

 Completed

 Upcoming


# CANNABICS® RCC-33

## Drug Candidate for treatment of Colorectal Cancer

### COLORECTAL CANCER (CRC)

- 3rd most commonly diagnosed worldwide
- 1,849,518 new cases in 2018 worldwide
- 2nd most lethal cancer worldwide
- 880,792 deaths in 2018 worldwide
- 67% of treated patients survive 5 years or more

Effect of Cannabics® RCC-33 on Tumor Development in Mice Inoculated with Human Colorectal Cancer Cell



27% reduction in tumor volume. P-Value = 0.022 (Day 17)

30% reduction in tumor volume. P-Value = 0.019 (Day 19)

33% reduction in tumor volume. P-Value = 0.016 (Day 21)


# CANNABICS® RCC-33

## Drug Candidate for treatment of Colorectal Cancer

### REGULATORY PATH

- Dose control POC ongoing
- Preparation of FDA Pre-IND Meeting package: ongoing

**Cannabics® RCC 33 Prolongs Survival Rate of Human Colorectal Tumor Bearing Mice**  
(Kaplan Meier survival analysis)



↓

**35% increased Survival Rate**

# LEADERSHIP

## BOARD OF DIRECTORS

### **Gabriel Yariv**

#### **Executive Chairman of the Board**

Mr. Yariv, 44, brings over 20 years of successful executive experience in the medical industry.

### **DR. Inbar Maymon-Pomeranchik**

#### **Independent Board Member**

Dr. Maymon-Pomeranchik, 43, is trained as a molecular and genetic researcher holding a PhD from the Hebrew University, and brings nearly 20 years of executive level experience in biotech sciences, with particular expertise in the global medical cannabis industry.

Dr. Maymon-Pomeranchik also serves on the boards of several public companies.

### **Eyal Barad**

#### **Board Member**

Mr. Barad serves also as CEO of Cannabics Pharmaceuticals

### **Shaul Yemal**

#### **Independent Board Member, Head of Audit Committee**

Mr. Yemal, brings decades of transnational management and finance experience. Mr. Yemal served as Senior Economist in the Division of Economic Consulting for the Ministry of Finance, Budget Division of the Minister of Finance and Manager of the Economic and Planning Division of the Ministry of Energy (Israel). Mr. Yemal was acting Chair of Financial, Auditor and Compensation Committees for numerous companies both public and private.

### **DR. Gil Feiler**

#### **Independent Board Member**

Dr. Feiler, 62, is a world-renowned economist and currently serves also as the company's Head of Advisory Board. Dr. Feiler holds a PhD in Middle East Economics from Tel Aviv University, and is a graduate of the International Management Program at the Israeli Institute of Technology, Technion. Dr. Feiler currently serves also as Director of the Bank of Georgia for the Middle East and North Africa, as Partner at Forest Investment House (\$1B AUM).

# LEADERSHIP

---

## MANAGEMENT

### **Eyal Barad** Co-Founder & CEO

Mr. Barad, 56, brings over 30 years of business leadership experience. Mr. Barad was a pioneer in the digital publishing and advertising industry and CEO of an international digital media company on Madison Ave in NYC for over 20 years.

### **Uri Ben-Or** CFO

Over 20 years of experience in corporate finance, accounting, M&A transactions, IPO's and operations.

# LEADERSHIP

---

## CLINICAL ADVISORY BOARD

### **Prof. Caroline Robert (MD)**

#### **Melanoma**

Prof. Caroline Robert, M.D., Ph.D., is a world-renowned expert on Melanoma. She is Head of the Dermatology Unit at Institut Gustave Roussy in Paris, France. She is also co-Director of the Melanoma Research Unit at INSERM 981 Paris-Sud University.

### **Prof. Amos Toren (MD)**

#### **Oncology**

Prof. Amos Toren is the Director of Pediatric Hemato-Oncology and BMT department at the Sheba Medical Center since 2001 and a Professor in the division of Hematology, Sackler school of medicine tel-aviv university. Prof. Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-oncology. He also has a Ph.D degree in genetics and qualified as a master of health administration (MHA) at the Recannati Business School, Tel-Aviv University.

### **Prof. Zamir Halpern (MD)**

#### **Gastroenterology**

Prof. Halpern, Senior Physician at the Gastroenterology institute in the Sourasky Medical Center in Tel-Aviv, Israel, served as Chairman of the Israeli Association of the Study of Liver, Chairman of the Israeli Gastroenterology Association, Chairman of the National Council for Food and Agriculture and is now Chairman of the National Gastro Nutrition and Liver Diseases Council at the Ministry of Health.

### **Prof. Noam Shomron (Ph.D.)**

#### **Big Data and AI**

Professor Noam Shomron is passionate about using basic science to advance better healthcare. Professor Shomron heads the Functional Genomic Team at the Faculty of Medicine at Tel Aviv University, after training at MIT. He leads a multidisciplinary team of scientists that develops computational methods for parsing big data in the bio-medical field using Artificial Intelligence. Shomron applied for more than 30 patents, published close to 200 peer-reviewed publications on multiple genomic fields including medicine, agriculture, and business.

# LEADERSHIP

---

## CLINICAL ADVISORY BOARD

### **Dr. Sigal Tavor (MD)**

#### **Hematology**

Dr. Tavor currently serves as a Senior Physician at the Hemato Oncology Institute, Assuta Medical Center, Tel-Aviv, Israel. Dr. Tavor is the former Acting Head of the Leukemia Unit, Department of Hematology and Bone Marrow Transplantation, Sourasky Medical Center, Tel Aviv, Israel. Dr. Tavor has completed two postdoctoral fellowships: at the Department of Hematology and Oncology, University of California Los Angeles, CA, and at the Department of Immunology, Weizmann Institute, Israel.

### **Dr. Dana Ben-Ami Shor (MD)**

#### **Gastroenterology**

Dr. Ben-Ami Shor is a recognized expert in invasive endoscopy and gastroenterology in the Sourasky Medical Center in Tel-Aviv, Israel. Dr. Ben-Ami Shor earned her M.D in 2009, graduating cum laude from the Sackler Faculty of Medicine, Tel Aviv University. She specialized in internal medicine and gastroenterology at the Sheba Medical Center, Israel.

### **Dr. Yonina Tova (MD)**

#### **Oncology**

Dr. Tova is an internationally recognized Radiation Oncologist. Dr. Tova is certified by the American Board of Radiology (ABR), and currently serves as Director of the Radiotherapy Institute at Ziv Hospital in Israel.

### **Dr. Erez Scapa (MD)**

#### **Gastroenterology**

Dr. Scapa earned his M.D in 2000 at the Technion Institute of Technology in Haifa, Israel, cum laude. He later held a Research Fellowship in Hepatology at the Brigham and Women's Hospital, Harvard University, Boston, MA, as well as a fellowship in Endoscopic Submucosal Dissection at the NTT Medical Center in Tokyo, Japan.

### **Dr. Sigalit Arieli Portnoy (Ph.D.)**

#### **Regulatory Affairs**

Dr. Sigalit Arieli-Portnoy has vast experience in the pharmaceutical industry and managed pharmaceutical and chemical plants at Taro Pharmaceutical Industries LTD as Operation Group Vice President and in Teva Pharmaceutical industries LTD as OSD plant manager.



# 3 Bethesda Metro Center  
700 Bethesda, MD 20814  
Phone: (877) 424-2429  
info@cannabics.com  
www.cannabics.com